Introduction
Articular cartilage lesions are characterized by the degeneration or injury of flexible cartilage over the articulating ends of bones [1] . While articular cartilage injuries can occur in any joint, they often develop and become problematic in the knee. PrevThe Knee xxx (xxxx) xxx between September 2014 and September 2017. Local ethics board approval was obtained from the Kantonale Ethikkommission, Zurich prior to starting this study. This study addresses the following clinical questions:
1. How often do patients who are treated with CARGEL require reoperations on the lesion that was treated with the microfracture and CARGEL? 2. What is the incidence of infection following treatment with CARGEL? 3. What is the incidence of allergic reactions following treatment with CARGEL? 4. What is the change in ROM from pre-surgery to post-surgery for patients treated with CARGEL? 5. What is the change in pain score from pre-surgery to post-surgery for patients treated with CARGEL? 6. What is the change in knee swelling from pre-surgery to post-surgery for patients treated with CARGEL? 7. What is the short-term quantity and quality of lesion repair tissue following treatment with CARGEL?
Eligibility criteria and consent process
All patients with articular cartilage defects treated with CARGEL scaffold and microfracture surgery between September 2014 to September 2017 and who had at least three months of follow-up were invited, by mail and telephone follow-up, to participate in the study. The indications for arthroscopic CARGEL scaffold and microfracture surgery included: symptomatic cartilage defect in femoral condyle, trochlea or patella; intact corresponding cartilage; Kellgren-Lawrence classification of osteoarthritis b grade 3; a stable knee; defect size b2 cm 2 ; and age b 50 years. Axis correction was indicated for axis deviation of N5°, which was confirmed by long leg X-rays. In cases where a varus deviation N 5°was confirmed and the defect was located in the medial femoral condyle, an open-wedged high tibia osteotomy (HTO) was recommended. In the case where the patient had cartilage damage to the lateral femoral condyle and valgus malalignment, a distal femoral osteotomy (DFO) was performed in the form of a medial closed-wedge osteotomy with a TomoFix™ plate.
Patients with cartilage damage to the patella were clinically and radiologically screened prior to surgery. All patients with cartilage damage to the patella received a medial arthrotomy, the patella was inverted and the defect treated in the same way as defects in other sites. To prevent unwanted shearing of CARGEL from the defect, the defect in patella cases was additionally covered by stitching of a ChondroGide® collagen membrane (Geistlich, Wolhusen, Switzerland). Treated patellofemoral instabilities in this study were trochlear dysplasia b Dejour type B. The study only included patients who did not have high-grade varus, valgus, or rotational defects. There were no corrections on the tibial tuberosity (Caton-Deschamps index b1.2, TT-TG distance b20 mm) performed. Patellofemoral instability was treated by reconstruction of the medial patellofemoral ligament according to the technique by Fink et al. [22, 23] Soft-tissue correction of active maltracking was performed by medial shortening of the retinaculum and capsule, and, if necessary, by additional covered lateral release.
Patients who agreed to participate provided written informed consent. Once informed consent was obtained, eligibility was confirmed by reviewing the participants' medical records.
Data collection
A medical student abstracted patient demographics, baseline characteristics, lesion characteristics, surgical details, and outcome data from the participants' medical records. Outcome data included rates of reoperation and second-look surgery, incidence of infection, ROM in degrees of flexion, and pain and swelling scores using a four-point Likert scale.
Baseline and post-treatment MRIs were anonymized and sent to independent musculoskeletal radiologists, who are not associated with the study participants' care, for review. To be included, the post-treatment MRIs must have been taken at least three months from the index procedure. The radiologists assessed coronal and sagittal fat saturated sequences and axial images, and determined the short-term quantity and quality of the lesion repair according to the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) II scoring system and using T2 relaxation time [20] . They assessed the index lesion on the pre-treatment MRI and on the post-treatment MRI. The pre-treatment values were compared with the post-treatment values.
Definition of the subgroup
A subgroup of patients with patellar lesions treated with CARGEL and microfracture plus ChondroGide membrane were identified. The analyses (see below) were repeated for this subgroup due to differences in surgical procedures (e.g. mechanical support and open technique).
Data analysis
Categorical variables were summarized using frequencies and proportions. The Wilcoxon signed-rank test was used to test differences in endpoints measured at baseline and at post-treatment follow-up visit. Continuous variables were evaluated using measures of central tendency (means, medians), mean difference, and spread (95% confidence intervals, standard deviations). The analyses were repeated on a subgroup of patients with patellar lesions treated with microfracture and CARGEL plus ChondroGide. All statistical analyses were performed using IBM® SPSS® Statistics Version 25.
Results

Participant characteristics
One hundred and eleven patients were invited to participate in the study and 91 provided informed consent for 93 index lesions to be included. No patients were excluded after the review of their medical records. The mean age of study participants was 42.2 years and the majority were male (72.5%) ( Table 1) . Fifty-two percent (51.6%) of patients were affected in the right knee, 46.2% in the left knee, and 2.2% in both knees. Eighty-one knee cartilage lesions were classified using the International Cartilage Repair Society (ICRS) evaluation system [24] . Overall index defects were classified as ICRS class II (3.2%), ICRS class III (50.5%) or ICRS class IV (33.3%). Localization of index lesions was identified among patients in the following regions: medial femoral condyle (40.9%), trochlea (32.3%), patella (16.1%), lateral femoral condyle (7.5%), and lateral tibial plateau (4.3%). In addition to the treatment of cartilage damage with CARGEL, 33.3% of lesions were treated by partial resection of the meniscus; 22.6% by bone drilling; 21.5% by cartilage debridement; 19.4% by arthrotomy; 16.1% by meniscal suture; 11.8% by arthroscopic anterior cruciate ligament reconstruction; 6.5% by reconstruction of the medial patellofemoral ligament, with five out of six of these patients treated by arthrotomy and cartilage repair with a combination of CARGEL and ChondroGide® membrane; and 12.9% by patellar balancing. Furthermore, 3.2% of patients were treated by open-wedged high tibial osteotomy to correct varus deformity, performed medially and on the proximal tibia in all cases, and stabilized with a TomoFix™ plate. A total of 1.1% of patients were treated by medial closed wedge distal femoral osteotomy to treat valgus malformation and stabilized with a distal femur plate (TomoFix™). Figure 1 depicts the femoral condyle in a 27-year-old male competitive athlete showing (a) debridement of lesion and microfracture and (b) filling with CARGEL plus autologous blood. Thirteen participants had index patellar lesions (14 index lesions in total) that were treated with microfracture and CARGEL plus ChondroGide collagen membrane for mechanical support in an open technique. Participants who had patellar lesions were slightly younger than the rest of the study population (mean 39.5 years) with a similar sex distribution (61.5% male) ( Table 2 ). All participants who had patellar lesions had an arthrotomy. A third of lesions treated in this group involved medial patellofemoral ligament reconstruction. Patellar lesions were classified with an ICRS grading distribution similar to lesions in other regions. All patellar lesions were treated alongside CARGEL with arthrotomy and more than half were treated with patellar balancing techniques. No lesions in this group were treated with partial resection of meniscus, cartilage debridement or meniscal suture.
Study outcomes
The mean length of participant follow-up was six months ±1.7 months, with a range of three to 12 months. No participants had a reoperation due to a complication at the index lesion. Fifteen participants had subsequent surgery on their index knee for other reasons. Six (6.6%) participants underwent second-look surgery for arthroscopic arthrolysis, four (4.4%) had manipulations under anesthesia, and the remaining five who required reoperation were operated on the same knee, but for defects other than the target lesion treated with CARGEL. The second-look surgery allowed for visual confirmation of the cartilage repair in all cases. Figure 2 shows the lesion from the patient in Figure 1 at a second-look procedure approximately six months from the index procedure. No second-look surgeries were due to complications for lesions that were treated with microfracture and CARGEL. None of the study participants experienced a post-surgical infection and none suffered an allergic reaction following treatment with CARGEL.
ROM pre-surgery and at follow-up was documented in the medical records of 67 patients (73.6%). The mean ROM prior to treatment with CARGEL was 135.5°±10.9. At post-surgery follow-up, the mean ROM was 136.9°± 6.1. The mean difference in ROM between baseline and post-surgery was 1.34°± 12.0, which was not statistically significant (Table 3 ). For patients with patellar lesions, the mean ROM prior to treatment with CARGEL was 134.5°± 15.7. At post-surgery follow-up, the mean ROM was 136.5°± 5.3. The mean difference in ROM between baseline and post-surgery was 2.0°± 17.8, which was not statistically significant. Pain scores were available for 73 (80.2%) participants. The median pain score was 2.0 pre-surgery and decreased significantly to 1.0 at six months' post-treatment (Z = −6.117, P b 0.001) ( Table 4 ). Swelling scores were available for 73 (80.2%) participants and the median swelling score was 1.0 pre-treatment and decreased significantly to 0.0 at six months' post-treatment (Z = −5.552, P b 0.001). For participants with patellar lesions, the median pain score was 2.0 pre-surgery and decreased significantly to 1.0 at six months' post-treatment (Z = −2.585, P = 0.010) ( Table 5 ). The median swelling score for participants with patellar lesions was 0.5 pre-treatment and remained 0.0 at six months' post-treatment (Z = −1.414, P = 0.157).
MOCART II scores increased significantly from pre-treatment (mean, 38.89 ± 19.6) to post-treatment (mean, 56.90 ± 27.2) (P b 0.001). T2 relaxation times for repair tissue were measured and mapped for participants. Figure 3 shows the resulting T2 scores six months' post-treatment of the same patient depicted in Figures 1 and 2 , including the corresponding T2 map identifying scores for each layer and control cartilage, and an MRI image of the defect. The short-term T2 relaxation times increased slightly from pre-treatment (mean, 41.62 ms ± 22.6) to post-treatment (mean, 45.73 ms ± 18.5) (P = 0.241) ( Table 6 ). In the patellar Table 7 ). Figure 4 shows an MRI of the same location at 12 months after treatment.
Discussion
In this cohort study of 91 patients and 93 index knee cartilage lesions treated with microfracture and CARGEL, no patients underwent reoperation due to complications at the index lesion. However, six (6.6%) participants underwent surgery for arthroscopic arthrolysis and four (4.4%) had manipulations under anesthesia. These procedures allowed for a second-look and visual confirmation of the cartilage repair in all cases. There were no infections or allergic reactions. Additionally, there was no change in ROM from pre-surgery to post-treatment follow-up, and significant decreases in pain and swelling from pre-treatment to posttreatment follow-up. Reviews of MRIs found significant improvements in MOCART II score assessing lesion quality and quantity, but no significant difference in the T2 relaxation times, which were likely due to the physiological healing process.
The rate of reoperation in this study is similar to those reported in the literature for cartilage regenerative techniques [25] . Consistent with the current cohort study, prior clinical studies that evaluated CARGEL did not report any postoperative infections or allergic reactions following treatment [12, 16] . CARGEL is contraindicated for use in patients with hypersensitivities to shellfish, active blood clotting disorders, receiving anti-coagulant therapy that cannot be interrupted, rheumatoid arthritis, or advanced musculoskeletal diseases. The absence of allergic reactions in this study reinforces findings that CARGEL is safe for use in patients outside of these vulnerable groups. Knee arthroscopy is one of the most commonly performed orthopedic procedures in the world [26] [27] [28] , and studies have shown that postoperative infection rates after knee arthroscopy are extremely low [29, 30] .
While the current study did not find any significant improvements in ROM from pre-treatment to post-treatment follow-up, it did find significant decreases in pain and swelling from pre-treatment to post-treatment. Prior studies did not report on ROM. Stanish et al. reported statistically significant improvements in pain from pre-treatment to 12 months' post-treatment on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [12] , and Shive et al. reported that these reductions in pain remained at five years' post-treatment [16] . Results in the current cohort study confirm the pain reductions found by Stanish et al. [12] and Shive et al. [16] , but the use of a Likert scale internal to the study clinic and not validated by others limited ability to make comparisons about the magnitude of the reductions that were found. The two previous clinical studies did not report on changes in swelling [12, 16] . The age distribution in the study population in these studies also differs from the current cohort study population. The mean age at the time of treatment in the previous clinical trial was 34.3 years ±9.7, while the mean age at treatment in the current cohort was 42.2 years ±9.8. This suggests that improvements in pain and swelling reported in the current cohort study demonstrate efficacy in an older population. a Wilcoxon signed-rank test used with reported Z statistic, P-value, and median for pre-treatment and post-treatment endpoint. Table 5 Changes in pain and swelling for the patellar subgroup.
Pre-treatment, median Post-treatment, median Z P There is evidence that patients with patellar lesions treated with bone-marrow stimulating techniques exhibit differences in clinical outcome compared to patients treated for cartilage defects in other locations of the knee [31, 32] . Mean filling of the patellar defects in animal models can be twice that of other areas of the knee in short-term follow-up [16] . In patients treated for cartilage lesions of the patella, larger defects were significantly associated with poor clinical outcomes, and defects located on the lateral patellar facet were correlated with improved clinical outcomes [17] . In this study, a subgroup of participants who had patellar lesions demonstrated significant decreases in pain consistent with the study population but did not demonstrate significant decreases in swelling. This is likely due to the small sample size. It could also be due to grouping patients with patellar defects rather than categorizing based on defect location within the patella. This cohort study found that treatment with CARGEL significantly improved quality and quantity of repair cartilage at shortterm follow-up in patients with articular cartilage lesions when compared to pre-surgery cartilage. Magnetic resonance imaging evaluation showed that treatment with CARGEL for articular damage in the knee resulted in good quantity and quality short tissue repair integrated into the surrounding tissue. The mean MOCART II score was 56.9 at follow-up, which was significantly higher than MOCART II scores pre-treatment. A significant increase in MOCART II scoring was also observed in the subgroup of patients with patellar defects, where the mean MOCART II score was 59.5 at follow-up. MOCART II increases observed in this study confirm early radiological results from other articular cartilage treatment studies that showed total MOCART II scores ranging from 41 to 75 at follow-up ranging from three to 12 months, when CARGEL was used for the treatment of articular cartilage defects of the knee [33, 34] . These increases also affirm recent findings that CARGEL treatment results in the improvement of several structural and cellular characteristics of repair tissue over microfracture [35] . This was demonstrated through visual assessments made during second-look arthroscopy to apply ICRS macroscopic scoring and histological assessments that showed significant improvement in surface architecture, surface/superficial assessment, cell viability, and cell distribution.
Overall, T2 relaxation time measurements increased slightly after CARGEL treatment for the study population and remained unchanged for the subgroup of patients with patellar defects, which is likely related to the ongoing physiological healing process and earlier timing of MRI. Previous studies evaluating T2 relaxation times in CARGEL reported significant decreases in T2 relaxation times for hyaline-like repair cartilage. In those studies, baseline MRI reference points were collected one month after treatment and follow-up was ≥2 years [11] . In contrast, in the current study, baseline MRI reference points were collected prior to treatment and post-treatment MRIs were taken at a mean of six months after surgery. Post-treatment reference points and a lengthier follow-up may yield different findings as the healing process progresses.
This cohort study was strengthened by the use of scoring systems for many of the outcomes, including the assessment of ROM, scores for pain, and scores for swelling. Another strength of the study was that the MRI review was conducted by independent experienced musculoskeletal radiologists, and that repair tissue quantity and quality were assessed using three-dimensional quantitative MRI imaging. This study was limited by its retrospective design. Additionally, follow-up was limited to a mean of six months' post-treatment, with a range from three to 12 months. Based on the literature, six months of follow-up is appropriate for assessing early post-surgical infection [36, 37] , and pain and swelling [27] . However, longer follow-up is necessary to adequately assess structural outcomes, including the quality and quantity of cartilage repair tissue, after the tissue has fully healed. Another limitation of this study was that all participants were operated on and assessed by the same orthopedic surgeon, thus limiting the generalizability of the results. However, this aspect also eliminated any inter-surgeon variability and ensured standardized treatment and follow-up.
The results of this retrospective cohort study found that patients treated with CARGEL did not require any reoperations due to complications related to CARGEL, experienced no infections or allergic reactions, and reported promising improvements in pain and swelling outcomes after treatment. Moreover, this study also showed that lesions treated with CARGEL had improved short-term cartilage tissue quantity and quality, as per the MOCART II score, when compared to pre-surgery lesions. This cohort study suggests that microfracture treatment with CARGEL is safe and effective for the management of articular cartilage lesions in the knee.
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